Search

Displaying results 2741 - 2750 of 7452 in total
  1. Drug

    Methoxsalen

    go.drugbank.com/drugs/DB00553
    ApprovedInvestigational

    A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.

    Categories: Antipsoriatics for Systemic Use, Antipsoriatics for Topical Use
  2. Drug

    Zytron

    go.drugbank.com/drugs/DB11768
    ApprovedWithdrawn

    DMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota. … Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation, Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic).

  3. Drug

    Hydrocortamate

    go.drugbank.com/drugs/DB00769
    Approved

    Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses.

  4. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023. … [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.

  5. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

  6. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully

  7. Drug

    Crofelemer

    go.drugbank.com/drugs/DB04941
    ApprovedInvestigational

    It is marketed under the brand name Fulyzaq and indicated for the symptomatic treatment of non-infectious diarrhea in adult patients with HIV/AIDS who are taking antiretroviral therapy.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Metamizole

    go.drugbank.com/drugs/DB04817
    ApprovedInvestigationalWithdrawn

    Approvals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).

    Products: DIPIRONA 1 GAMPOLLA POR 2 ML
  9. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.

  10. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [A189006,A189030] Whereas historically popular pharmacologic treatments for insomnia (e.g. … potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the beginning of a new wave of treatment options for